

Appl. No. 09/857,333
Response filed December 8, 2003
Reply to Office Action of October 6, 2003

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Previously Presented) A method for treating inflammation in an animal having inflammation caused by one or more of immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, or cystitis, comprising administering to the animal an effective amount of a composition comprising:

- (a) a mycobacterial deoxyribonucleic acid obtained from a disrupted mycobacterium, the mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC); and
- (b) a pharmaceutically acceptable carrier, wherein the amount is effective to treat the inflammation.

2. (Currently Amended) A method for ~~preventing~~ reducing inflammation in an animal, comprising administering to the animal at risk of experiencing inflammation from immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, or cystitis, an effective amount of a composition comprising:

- (a) a mycobacterial deoxyribonucleic acid obtained from a disrupted mycobacterium, the mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC); and
- (b) a pharmaceutically acceptable carrier, wherein the amount is effective to ~~prevent~~ reduce the inflammation.

3-10. Previously cancelled

Appl. No. 09/857,333
Response filed December 8, 2003
Reply to Office Action of October 6, 2003

11. (Original) The method of Claim 1, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.
12. (Original) The method of Claim 2, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.
13. (Original) The method of Claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
14. (Original) The method of Claim 2, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
15. (Previously Cancelled)
16. (Currently Amended) A method for treating inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to ~~prevent~~ treat the inflammation.
17. (Currently Amended) A method for ~~preventing~~ reducing inflammation in an animal, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to ~~prevent~~ reduce the inflammation.
18. (Original) The method of Claim 16, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.

Appl. No. 09/857,333
Response filed December 8, 2003
Reply to Office Action of October 6, 2003

19. (Original) The method of Claim 17, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.
20. (Original) The method of Claim 16, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
21. (Original) The method of Claim 17, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
22. (Previously Presented) A method for treating inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising a mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to induce the synthesis of cytokine IL-10 and treat the inflammation.
23. (Previously Presented) A method for ~~preventing~~ treating inflammation in an animal, comprising administering to the animal an effective amount of a composition comprising a mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to induce the synthesis of cytokine IL-10 and ~~prevent~~ treating the inflammation.
24. (Previously Presented) The method of Claim 1, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.
25. (Previously Presented) The method of Claim 2, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

Appl. No. 09/857,333
Response filed December 8, 2003
Reply to Office Action of October 6, 2003

26. (Previously Presented) The method of Claim 22, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

27. (Previously Presented) The method of Claim 23, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.